Comparison tool

Semaglutide Oral vs Semaglutide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

Semaglutide OralSemaglutide

Share this peptide comparison

Property	Semaglutide Oral	Semaglutide
Category	Weight Loss	Weight Loss
Also known as	Semaglutide Oral, Rybelsus, Semaglutide	Ozempic, Wegovy, Rybelsus
FDA approved	Yes	Yes
Clinical status	FDA approved for Rybelsus in type 2 diabetes; cardiovascular-risk reduction (Oct 2025); and weight management with oral Wegovy 25 mg (Dec 2025), which the source calls the first oral GLP-1 for obesity. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Oral use in type 2 diabetes and weight management.	Weight loss, appetite control, blood sugar management
How it works	The supplied record identifies semaglutide as a GLP-1 receptor agonist and attributes appetite reduction, slower gastric emptying, and glucose-dependent insulin release to it. It describes co-formulation with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which is said to alter local gastric pH, limit digestive peptide breakdown, and facilitate passage through the gastric lining into blood. These mechanistic statements were not independently corroborated in the input.	According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.
Typical dosing	Limited community data available · See research protocols	1-2.4 mg weekly (after titration) · Once weekly
Research dosing	3mg daily (starting) · Long-term / chronic use · Oral tablet on empty stomach with <4oz water	0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)
Typical duration	Long-term / chronic use	Long-term / chronic use
Administration	Oral tablet on empty stomach with <4oz water	Subcutaneous injection weekly, or oral (Rybelsus)
Timing	Morning, immediately after waking, on an empty stomach The source associates empty-stomach administration with a 30 minute separation from food and additional fluid.	Morning, same day each week With or without food
Evidence level	FDA Approved	FDA Approved
Possible side effects	Nausea (Reported by the source at up to 50 %; it notes that response can vary with dose, duration, and individual health factors.) Vomiting Diarrhea +4 more Constipation Pancreatitis Gallbladder problems Thyroid C-cell tumors (The source labels this a BOXED WARNING.)	Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.) Vomiting Diarrhea +10 more Constipation Abdominal pain Headache Fatigue Injection site reactions Hypoglycemia (Source associates this report with insulin/sulfonylureas.) Gallbladder problems Pancreatitis Acute kidney injury Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)
Research summary	The supplied record characterizes the evidence as published human-trial research. It reports that PIONEER included more than 9,500 people with type 2 diabetes, with A1C changes of roughly 0.6 to 1.4 percentage points and modest weight loss; sitagliptin and empagliflozin are named as comparators. For PIONEER PLUS, cited as published in The Lancet, the record compares 25 mg and 50 mg with 14 mg and reports greater A1C and weight reductions at the higher amounts. It reports an OASIS 1 comparison of 15.1 % weight loss at 50 mg versus 2.4 % with placebo. For OASIS 4 (NEJM, 2025), it states 13.6 % loss at a 64 week endpoint on 25 mg, described as comparable with injectable Wegovy. These reported results require review against the cited publications.	The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.
References	Source Source +3 more Source Source Source	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Semaglutide Oral

Semaglutide

Category

Weight Loss

Also known as

Semaglutide Oral, Rybelsus, Semaglutide

Ozempic, Wegovy, Rybelsus

FDA approved

Yes

Clinical status

FDA approved for Rybelsus in type 2 diabetes; cardiovascular-risk reduction (Oct 2025); and weight management with oral Wegovy 25 mg (Dec 2025), which the source calls the first oral GLP-1 for obesity.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Oral use in type 2 diabetes and weight management.

Weight loss, appetite control, blood sugar management

How it works

The supplied record identifies semaglutide as a GLP-1 receptor agonist and attributes appetite reduction, slower gastric emptying, and glucose-dependent insulin release to it. It describes co-formulation with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which is said to alter local gastric pH, limit digestive peptide breakdown, and facilitate passage through the gastric lining into blood. These mechanistic statements were not independently corroborated in the input.

According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.

Typical dosing

Limited community data available · See research protocols

1-2.4 mg weekly (after titration) · Once weekly

Research dosing

3mg daily (starting) · Long-term / chronic use · Oral tablet on empty stomach with <4oz water

0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)

Typical duration

Long-term / chronic use

Administration

Oral tablet on empty stomach with <4oz water

Subcutaneous injection weekly, or oral (Rybelsus)

Timing

Morning, immediately after waking, on an empty stomach

The source associates empty-stomach administration with a 30 minute separation from food and additional fluid.

Morning, same day each week

With or without food

Evidence level

FDA Approved

Possible side effects

Nausea (Reported by the source at up to 50 %; it notes that response can vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+4 more

Constipation
Pancreatitis
Gallbladder problems
Thyroid C-cell tumors (The source labels this a BOXED WARNING.)

Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+10 more

Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia (Source associates this report with insulin/sulfonylureas.)
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)

Research summary

The supplied record characterizes the evidence as published human-trial research. It reports that PIONEER included more than 9,500 people with type 2 diabetes, with A1C changes of roughly 0.6 to 1.4 percentage points and modest weight loss; sitagliptin and empagliflozin are named as comparators. For PIONEER PLUS, cited as published in The Lancet, the record compares 25 mg and 50 mg with 14 mg and reports greater A1C and weight reductions at the higher amounts. It reports an OASIS 1 comparison of 15.1 % weight loss at 50 mg versus 2.4 % with placebo. For OASIS 4 (NEJM, 2025), it states 13.6 % loss at a 64 week endpoint on 25 mg, described as comparable with injectable Wegovy. These reported results require review against the cited publications.

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

References

+3 more

+2 more

Full profile